At #ASH23, Reid Merryman, MD, Dana-Farber, discussed results from a pilot study that uses circulating tumor DNA to reliably predict relapse in patients with diffuse large B-cell lymphoma.
Dr. Merryman received his undergraduate degree from the University of Notre Dame and his medical degree from Harvard Medical School. He completed residency training in internal medicine at Brigham and Women's Hospital and fellowship training ...
